VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug
Synopsis
This is the second Vanda drug to be approved in the span of a few months, after the approval of Nereus in December.
Shares of Vanda Pharmaceuticals Inc. (VNDA) rose 2% after hours on Friday after the U.S. Food and Drug Administration approved the company’s Bysanti tablets for the treatment of certain mental health conditions.
The FDA approved the drug for acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia in adults. The company expects the drug to be available in the market in the third quarter of 2026.
This is the second Vanda drug to be approved in the span of a few months — its Nereus drug was approved in December.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.